Loading clinical trials...
Loading clinical trials...
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Calibr, a division of Scripps Research
NCT06191744 · Follicular Lymphoma (FL)
NCT07397832 · Diffuse Large B-Cell Lymphoma (DLBCL)
NCT06043011 · Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), and more
NCT05888493 · Follicular Lymphoma (FL)
NCT05583149 · Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, and more
City of Hope National Medical Center
Duarte, California
University of California at San Diego
San Diego, California
University of Chicago
Chicago, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions